Frontiers paper proposes intermittent liraglutide added to low-dose tirzepatide

The wire

1. 01A hypothesis paper in Frontiers in Endocrinology proposes adding intermittent low-dose liraglutide, illustratively 0.6 mg every 48 to 72 hours, to a stable low-dose tirzepatide background to re-engage GLP-1 receptor signalling.
2. 02Clinicians may see patients asking about stacking agonists; the authors state prescribing information for both products does not recommend coadministration with another GLP-1 receptor agonist.
3. 03This is a hypothesis with no clinical or preclinical data behind it. The authors say the combination must not be used outside an ethics-approved trial and that the 48-hour interval requires formal pharmacokinetic characterisation.

From the source

Pulsatile liraglutide on a biased tirzepatide background: a hypothesis

Frontiers in endocrinology · 2026 · Kopitovic I et al.